Mutya Harsch
CIK 1727809 · CHIEF LEGAL OFFICER AND GC · last filed 2026-07-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$54.8K
Companies
4
Total Filings
52
Lifetime Open-Market Net
$14.1K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VYNE | CHIEF LEGAL OFFICER AND GC | 1,918 | $28.56 | $54.8K | $25.0K | 34 | 2026-07-24 |
| Satsuma Pharmaceuticals, Inc. (STSA) Delisted | Director | — | $1.10 | — | $0 | 3 | 2023-06-08 |
| VYNE Therapeutics Inc. (MNLO) Delisted | Chief Legal Officer and GC | 318,887 | — | — | $0 | 5 | 2020-07-02 |
| Foamix Pharmaceuticals Ltd. (FOMX) Delisted | CLO and General Counsel | 98,232 | — | — | -$10.9K | 9 | 2020-03-03 |
Recent Filings · Page 2 of 6
52 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-10-02 | VYNE | Tax (F) | −105 | -$197 | EDGAR |
| 2024-07-03 | VYNE | Tax (F) | −143 | -$275 | EDGAR |
| 2024-04-03 | VYNE | Tax (F) | −161 | -$496 | EDGAR |
| 2024-01-03 | VYNE | Mixed | +62,339 | -$367 | EDGAR |
| 2023-12-15 | VYNE | Grant (A) | +62,500 | $0 | EDGAR |
| 2023-10-04 | VYNE | Tax (F) | −1,154 | -$4.4K | EDGAR |
| 2023-07-05 | VYNE | Tax (F) | −157 | -$644 | EDGAR |
| 2023-06-08 | Satsuma Pharmaceuticals, Inc. (STSA) Delisted | Disp (D) | — | $0 | EDGAR |
| 2023-06-02 | VYNE | Grant (A) | +3,664 | $12.7K | EDGAR |
| 2023-04-04 | VYNE | Tax (F) | −478 | -$1.5K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.